Ampreloxetine
- Generic Name
- Ampreloxetine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18F3NO
- CAS Number
- 1227056-84-9
- Unique Ingredient Identifier
- 19997EZ42I
- Background
Ampreloxetine is under investigation in clinical trial NCT03750552 (Clinical Effect of TD-9855 for Treating snOH in Subjects With Primary Autonomic Failure).
- Associated Conditions
- -
- Associated Therapies
- -
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 102
- Registration Number
- NCT05696717
- Locations
- 🇺🇸
TBPH Investigative Site, Boston, Massachusetts, United States
🇫🇷Centre d'Investigation Clinique Hôpital Pierre Paul Rique, Toulouse, France
🇺🇸Movement Disorders Center of Arizona, Scottsdale, Arizona, United States
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855
- Conditions
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 31
- Registration Number
- NCT04200573
- Locations
- 🇺🇸
Theravance Biopharma Investigational Site, Orlando, Florida, United States
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2022-11-30
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 110
- Registration Number
- NCT04095793
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸NorthShore University HealthSystem, Glenview, Illinois, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 203
- Registration Number
- NCT03829657
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
- Conditions
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 195
- Registration Number
- NCT03750552
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
🇺🇸NorthShore University Health System, Glenview, Illinois, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.